DIREKT: Disarming the intravascular innate immune response to improve modalities for chronic kidney disease treatment

DIREKT：解除血管内先天免疫反应以改善慢性肾脏病的治疗方式

• 批准号: nhmrc : 1074171
• 负责人: Prof Karen Dwyer
• 金额: $ 24.19万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Targeted Calls
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/direkt-disarming-intravascular-disease-treatment/455583
• 关键词: DIREKT; Disarming; intravascular; innate; immune

Dialysis is the mainstay treatment for patients with end-stage kidney disease while they await transplantation. However, the dialysis process causes inflammation in patients, affecting their health and longevity. This project aims to develop new bioreagents that can be applied to dialysis devices to reduce inflammation and thus improve patient outcomes. These bioreagents will also be used to modify donor kidneys so that they are protected from inflammation associated with transplantation.

透析是终末期肾病患者等待移植的主要治疗方法。然而，透析过程会引起患者炎症，影响他们的健康和寿命。该项目旨在开发可应用于透析设备的新型生物反应器，以减少炎症，从而改善患者的预后。这些生物试剂也将用于修饰供体肾脏，使其免受移植相关炎症的影响。